These data demonstrate that losartan is a potential therapy for the control of obesity-induced abnormal insulin sensitivity by regulating lipotoxic and HIF1α-dependent macrophage polarization. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.